These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32606935)

  • 1. Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients.
    Liu C; Zhang Z; Ping Y; Qin G; Zhang K; Maimela NR; Huang L; Yang S; Zhang Y
    Cancer Manag Res; 2020; 12():4399-4410. PubMed ID: 32606935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma.
    Zhang C; Zhang Z; Li F; Shen Z; Qiao Y; Li L; Liu S; Song M; Zhao X; Ren F; He Q; Yang B; Fan R; Zhang Y
    Oncoimmunology; 2018; 7(11):e1461304. PubMed ID: 30377558
    [No Abstract]   [Full Text] [Related]  

  • 3. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
    Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L
    Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
    Liu S; Zhang C; Maimela NR; Yang L; Zhang Z; Ping Y; Huang L; Zhang Y
    Oncoimmunology; 2019; 8(7):1601478. PubMed ID: 31143523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune and Clinical Features of
    Zhang Q; Zhong H; Fan Y; Liu Q; Song J; Yao S; Cao F
    Front Bioeng Biotechnol; 2020; 8():592. PubMed ID: 32695752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma.
    Chen L; Xiong Z; Zhao H; Teng C; Liu H; Huang Q; Wanggou S; Li X
    Front Oncol; 2022; 12():889351. PubMed ID: 36033495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.
    Li G; Wang Z; Zhang C; Liu X; Cai J; Wang Z; Hu H; Wu F; Bao Z; Liu Y; Zhao L; Liang T; Yang F; Huang R; Zhang W; Jiang T
    Oncoimmunology; 2017; 6(8):e1328339. PubMed ID: 28919992
    [No Abstract]   [Full Text] [Related]  

  • 8. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
    Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
    Front Genet; 2022; 13():1053263. PubMed ID: 36712869
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma.
    Yuan Y; Zhao Q; Zhao S; Zhang P; Zhao H; Li Z; Du Y; Tian X; Lu J
    Cancer Med; 2019 Jul; 8(8):3811-3821. PubMed ID: 31140757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 related transcriptome profile and clinical outcome in diffuse gliomas.
    Liu S; Wang Z; Wang Y; Fan X; Zhang C; Ma W; Qiu X; Jiang T
    Oncoimmunology; 2018; 7(2):e1382792. PubMed ID: 29308304
    [No Abstract]   [Full Text] [Related]  

  • 11. Transcriptome profile and clinical characterization of ICOS expression in gliomas.
    Wang J; Shi F; Shan A
    Front Oncol; 2022; 12():946967. PubMed ID: 36276141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.
    Wang Z; Zhang C; Liu X; Wang Z; Sun L; Li G; Liang J; Hu H; Liu Y; Zhang W; Jiang T
    Oncoimmunology; 2016; 5(11):e1196310. PubMed ID: 27999734
    [No Abstract]   [Full Text] [Related]  

  • 13. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.
    Wang ZL; Li GZ; Wang QW; Bao ZS; Wang Z; Zhang CB; Jiang T
    Oncoimmunology; 2019; 8(2):e1541535. PubMed ID: 30713802
    [No Abstract]   [Full Text] [Related]  

  • 15. CD44-Mediated Poor Prognosis in Glioma Is Associated With M2-Polarization of Tumor-Associated Macrophages and Immunosuppression.
    Xiao Y; Yang K; Wang Z; Zhao M; Deng Y; Ji W; Zou Y; Qian C; Liu Y; Xiao H; Liu H
    Front Surg; 2021; 8():775194. PubMed ID: 35187044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
    Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX
    J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large-Scale Analysis Reveals the Specific Clinical and Immune Features of DGCR5 in Glioma.
    Wu X; Hou P; Qiu Y; Wang Q; Lu X
    Onco Targets Ther; 2020; 13():7531-7543. PubMed ID: 32801772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples.
    Di W; Fan W; Wu F; Shi Z; Wang Z; Yu M; Zhai Y; Chang Y; Pan C; Li G; Kahlert UD; Zhang W
    Cancer Sci; 2022 Feb; 113(2):756-769. PubMed ID: 34881489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stanniocalcin 1 is a prognostic biomarker in glioma.
    Luo W; Chen D; Wang H; Hu J
    Oncol Lett; 2020 Sep; 20(3):2248-2256. PubMed ID: 32782542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific clinical and immune features of CD68 in glioma via 1,024 samples.
    Wang L; Zhang C; Zhang Z; Han B; Shen Z; Li L; Liu S; Zhao X; Ye F; Zhang Y
    Cancer Manag Res; 2018; 10():6409-6419. PubMed ID: 30568502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.